Clinical trial NCT02369211
Conditions: Prostatectomy Pain
Keywords: acetaminophen
Sponsor: Brigham and Women's Hospital
Start date: 2015-09-01; Completion date: 2018-03-01
Enrollment: 86 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
To examine pharmacoeconomics of IV acetaminophen (Ofirmev). Specifically, to examine its potential to improve hospital efficiency and patient outcomes. The investigators compare the addition of IV acetaminophen versus placebo on postoperative anesthesia care unit recovery times, inpatient hospital length of stay (LOS), postoperative pain scores, consumption of opiates as rescue agents and side effects among patients undergoing robotic-assisted laparoscopic prostatectomy (RALP).

Detailed description:
Although IV acetaminophen has been studied in urologic surgery, it has not been studied specifically in prostatectomies, and therefore there are no outcomes or cost-effectiveness data currently available. In addition, the current trend is to perform prostatectomy with a robot-assisted laparoscopic technique to help minimize incision size, blood loss, postoperative pain, and speed up patient recovery. Current literature only includes the use of opioids in the perioperative setting for robot-assisted prostatectomy to treat pain, but only a small trial used oral acetaminophen as a measure for analgesia in RALP. In addition to the decreasing use of opioids in perioperative pain management, emphasis has been placed on reducing costs of healthcare. A major contributor to this issue is hospital length of stay (LOS) and there has been increased pressure on healthcare providers to decrease overall LOS. Several factors may contribute to hospital LOS, including hospital acquired infections, surgical recovery, wound care, other surgical and anesthesia-related complications, and importantly, inadequate pain control.

In this study we examine the impact of adding IV acetaminophen to the multimodal analgesic regimen for robotic-assisted laparoscopic prostatectomy (RALP). Our hypothesis is that the addition of IV acetaminophen can improve postoperative recovery time, inpatient LOS, postoperative pain scores, and opioid consumption.

This study specifically addresses pharmacoeconomics of IV acetaminophen. The goal is to understand its potential to improve hospital efficiency and patient outcomes. The study compares the impact of the addition of IV acetaminophen versus a placebo on postoperative anesthesia care unit recovery times, inpatient LOS, postoperative pain scores, consumption of opiates as rescue agents and side effects in patients undergoing RALP.

The study is a 2-arm, double-blind, randomized, placebo controlled trial comparing IV acetaminophen to a control (IV placebo). All patients in this study were scheduled to undergo RALP.

Arms: arm 1: Patient receives 1g intravenous acetaminophen after the incision arm 2: Patient receives saline injection instead of the study drug
Interventions: intervention 1: Acetaminophen (Ofirmev) intervention 2: Placebo
Intervention descriptions: intervention 1: The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs. intervention 2: The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.

Protocol documents:
Prot_SAP_000.pdf: 
 
1 
STUDY PROTOCOL AND STATISTICAL ANALYSIS PLAN 
 
 
Title: Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous 
Acetaminophen (OFIRMEV) 
 
 
NCT02369211 
 
Document Date: 05/16/2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
2 
 
 
Purpose: In this study we examine the impact of adding IV acetaminophen to the multimodal 
analgesic regimen for robotic-assisted laparoscopic prostatectomy (RALP). We analyze whether 
adding IV acetaminophen can improve postoperative recovery time, inpatient hospital length of 
stay (LOS), postoperative pain scores, and opioid consumption. 
 
 
Methods:  
The study design is a 2-arm, double-blind, randomized, placebo-controlled trial comparing IV 
acetaminophen to a control (IV placebo). All patients will be provided written informed consent. 
All patients in this study are scheduled to undergo robotic-assisted laparoscopic 
prostatectomy (RALP). Other inclusion criteria are male patients at least 18 years of age 
who are ASA Physical Status 1-4. Exclusion criteria include chronic opioid use, liver disease 
(known history of hepatitis B or C, cirrhosis, nonalcoholic steatohepatitis, history of alcoholism, 
ALT/AST greater than 3 times upper limit of normal in the past 3 months), allergy/hypersensitivity 
to acetaminophen, baseline dementia, chronic diathesis, and chronic kidney disease. 
 
Primary outcome is PACU (post-anesthesia care unit) LOS (length of stay). Patients undergoing 
RALP will be enrolled in this study and randomly assigned to receive either 1 gram IV 
acetaminophen or IV placebo within 15 minutes following the induction of anesthesia and prior to 
surgical incision. All patients will undergo general endotracheal anesthesia with standardized 
anesthetic technique consisting of anesthesia induction with propofol 2–2.5 mg/kg, fentanyl 50–
100 mcg, and a non-depolarizing neuromuscular agent. General anesthesia is maintained with an 
inhalational agent (either desflurane or sevoflurane). All patients receive ketorolac 30 mg, 
ondansetron 4 mg, as well as hydromorphone (based on anesthesia provider’s decision, up to 1 mg) 
prior to emergence from anesthesia. Baseline pain is recorded using the Visual Analog Scale 
(VAS). These measures will be again recorded on transport to the PACU and again every 30 
minutes for 2 hours. Pain scores will be recorded at 8 random distinct time points in the first 24 
hours after discharge from the PACU and 8 time points in the second 24 hours post-PACU 
discharge. Repeat doses of IV acetaminophen or placebo will be given to each respective group 
every 6 hours for a total of 4 doses. Total opioid consumption during hospital stay was also 
recorded for each patient. Because opioid choice may be variable due to physician preference, total 
opioid use will be standardized and converted to PO morphine equivalents (based on APS 
equianalgesic table). PACU LOS in minutes will be calculated from the time of admission in the 
electronic health record (EHR) to the point where the patient was charted as “ready for discharge” 
from the PACU in the EHR. LOS on the hospital floor in days is calculated from the time point of 
“ready for discharge” from the PACU to the time point where the patient was charted as “ready for 
discharge” from the hospital in the EHR. For both time measurements, patients without time 
records or negative LOS will be removed for the analysis. 
 
Statistical analysis 
Assuming a difference of 12 minutes of PACU LOS between IV acetaminophen and IV 
placebo group, with a common within group standard deviation (SD) of 24 minutes, recruiting 44 
patients for each group would enable the investigators to reject the null hypothesis that the two 


 
3 
groups have equal mean with 90% power at significance level of 0.05. Sample size calculation was 
performed using SAS 9.3 software (SAS Institute Inc., Cary, NC, USA). 
 
Specific data variables collected for the study include: LOS on the hospital floor (LOS, calculated 
in days), PACU LOS (measured as the time from arrival to the PACU to the exact time the patient 
met discharge to the inpatient floor criteria by meeting Aldrete score thresholds, as documented by 
the PACU staff (measured in minutes), pain scores (using numeric rating scale 0-10, VAS scale), 
total opioid consumption (PO or IV) in the PACU and daily during hospital stay (total measured in 
morphine equivalents). Baseline characteristics include smoking history (yes or no), body mass 
index (BMI) in kg/m2, baseline pre-op pain scores (0-10, VAS scale), whether or not 
dexamethasone was used in surgery (yes or no), whether or not patient had chronic pain of 6 
months or more (yes or no), and patient age in years. Primary endpoints for the study were total 
PACU LOS measured in minutes and LOS on the hospital floor measured in days. Secondary 
endpoints include VAS pain score and total opioid consumption (PO of IV) in morphine 
equivalents (APS equianalgesic table). Continuous variables will be examined using Shapiro-Wilk 
test for normality assumption. Both age and PACU LOS will be calculated using mean values and 
SDs, as well as postoperative pain scores from immediate after surgery to 24 hours after surgery, 
while all other continuous variables will be calculated using median values and interquartile 
ranges. Categorical variables (smoking history, chronic pain, dexamethasone) will be calculated 
using frequencies and percentages. The differences in patient preoperative characteristics, as well 
as postoperative outcomes, between IV acetaminophen and IV placebo groups will be compared 
using two-sample t-test, Wilcoxon ranksum test, Chi-square test, Fisher’s exact test, repeated 
measures ANOVA, when deemed appropriate. Additionally, multiple linear regression will be used 
for evaluating the effect of IV acetaminophen on PACU LOS after adjusting for patient 
preoperative characteristics. Generalized linear model with gamma distribution and log link 
function will be used to estimate the effect of IV acetaminophen on LOS on the hospital floor, 
adjusting for the same set of patient preoperative characteristics. The pain scores from immediate 
postop to 2 hours, from immediate postop to 24 hours after surgery will be calculated at each time 
point respectively. The comparison of postoperative pain scores between IV acetaminophen and IV 
placebo groups will be performed using repeated measures ANOVA. Other comparisons between 
the two groups will be done using Wilcoxon ranksum test. All statistical hypothesis tests will be 
two sided, with p-value <0.05 considered statistically significant. Statistical analyses will be 
performed with SAS version 9.4 software (SAS Institute Inc., Cary, NC, USA).